{"nctId":"NCT00666211","briefTitle":"Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain","startDateStruct":{"date":"2005-05"},"conditions":["Brain and Central Nervous System Tumors","Chronic Myeloproliferative Disorders","Leukemia","Lymphoma","Lymphoproliferative Disorder","Multiple Myeloma and Plasma Cell Neoplasm","Myelodysplastic Syndromes","Myelodysplastic/Myeloproliferative Neoplasms","Pain","Precancerous Condition","Unspecified Adult Solid Tumor, Protocol Specific"],"count":98,"armGroups":[{"label":"Standard of Care","type":"ACTIVE_COMPARATOR","interventionNames":["Other: educational intervention","Other: questionnaire administration"]},{"label":"Opioid Titration","type":"EXPERIMENTAL","interventionNames":["Other: educational intervention","Other: Titrated pain management","Other: questionnaire administration"]}],"interventions":[{"name":"educational intervention","otherNames":[]},{"name":"Titrated pain management","otherNames":[]},{"name":"questionnaire administration","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Histologically confirmed carcinoma\n* Cancer-related pain requiring fixed-dose opioid therapy\n\n  * Has received ≥ 1 week of fixed-dose opioid therapy AND meets any of the following criteria:\n\n    * Inadequate pain control as defined by the patient\n    * Requires 2 or more rescue doses per day\n    * Requires adjustments in pain regimen (either fixed or breakthrough dosing)\n* No pain crisis that requires hospitalization or immediate anesthetic or neurosurgical intervention\n* No predominantly neuropathic pain (e.g., peripheral neuropathy) as assessed by the treating physician\n\nPATIENT CHARACTERISTICS:\n\n* ECOG performance status 0-2\n* ANC \\> 1,500/mm³\n* Platelet count \\> 100,000/mm³\n* Serum bilirubin \\< 1.5 mg/dL\n* Serum creatinine \\< 2.5 mg/dL\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* Nutritional, pulmonary, and cardiac status must be considered adequate to tolerate the proposed study therapy\n* Must be available for active follow-up\n* No documented active psychiatric disorder (i.e., psychosis or major depression) that would preclude informed consent or the patient's ability to comply with study procedures\n* No significant infection\n* No concerns about compliance with medication regimens or medical follow-up\n* No excessive alcohol use\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* Concurrent chemotherapy or radiotherapy allowed","healthyVolunteers":false,"sex":"ALL","minimumAge":"21 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Pain Intensity","description":"Patients in each arm will each have 9 measures: daily scores averaged over 1 week with baseline to week 8:\n\n1. Average daily pain intensity 0 (no pain) to 10 (worst) scale\n2. Worst daily pain intensity 0 (no pain) to 10 (worst) scale","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.60","spread":"2.76"},{"groupId":"OG001","value":"6.44","spread":"1.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.11","spread":"2.45"},{"groupId":"OG001","value":"5.98","spread":"1.96"}]}]}]},{"type":"SECONDARY","title":"Ability to Engage in Activities of Daily Living (ADL)","description":"The Functional Assessment Screening Questionnaire (FASQ) scale is used, scored at baseline and at weeks 2, 4, 6, 8. The FASQ consists of 15 questions about ability to perform ADL with minimum score of 1 (easy to perform) to a maximum score of 5 (N/A, meaning someone else performs this activity for the patient or else the patient chooses not to do it). A summary mean score is generated with a minimum score of 1 and a maximum score of 5.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.18","spread":"0.61"},{"groupId":"OG001","value":"1.99","spread":"0.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.14","spread":"0.73"},{"groupId":"OG001","value":"2.06","spread":"0.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.94","spread":"0.57"},{"groupId":"OG001","value":"1.91","spread":"0.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.01","spread":"0.73"},{"groupId":"OG001","value":"2.03","spread":"0.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.98","spread":"0.67"},{"groupId":"OG001","value":"1.96","spread":"0.58"}]}]}]},{"type":"SECONDARY","title":"Interference in Daily Life Due to Pain","description":"Patients in each arm will each have 5 measures on the Brief Pain Inventory (BPI) scale: baseline + weeks 2, 4, 6, 8. The BPI consists of 7 questions about interference of pain in daily life, answered on a scale of 0 (does not interfere) to 10 (completely interferes). The summary score is the average from the 7 questions, with higher score indicating greater interference due to pain.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.49","spread":"2.54"},{"groupId":"OG001","value":"4.23","spread":"2.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.25","spread":"2.89"},{"groupId":"OG001","value":"4.12","spread":"2.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.16","spread":"2.82"},{"groupId":"OG001","value":"3.48","spread":"2.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.78","spread":"2.99"},{"groupId":"OG001","value":"3.16","spread":"2.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.01","spread":"2.43"},{"groupId":"OG001","value":"3.68","spread":"2.42"}]}]}]},{"type":"SECONDARY","title":"Mood Disturbance","description":"Patients in each arm will each have 5 measures on the Profile of Mood States-Short Form (POMS-SF): baseline + weeks 2, 4, 6, 8. The POMS-SF consists of 37 questions, querying 6 mood states (anxiety, depression, anger, confusion, fatigue, and vigor), with responses on a scale from 0 (not at all) to 4 (extremely). To generate a summary score, questions on vigor state are first recoded to reverse the scale, so that higher summary scores consistently indicate greater mood disturbance.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.48","spread":"0.55"},{"groupId":"OG001","value":"1.21","spread":"0.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.45","spread":"0.63"},{"groupId":"OG001","value":"1.20","spread":"0.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.37","spread":"0.70"},{"groupId":"OG001","value":"1.12","spread":"0.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.19","spread":"0.64"},{"groupId":"OG001","value":"1.22","spread":"0.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.14","spread":"0.58"},{"groupId":"OG001","value":"1.32","spread":"0.70"}]}]}]},{"type":"SECONDARY","title":"Quality of Life","description":"Each patient in each arm is scored on the Functional Assessment of Cancer Therapy-General (FACT-G) at baseline + week 8 with 4 related sub-scales (physical, social/family, emotional, functional well-being. To generate sub-scale scores, physical and emotional items are reverse coded \\& items are then summed, such that higher values indicate better quality of life. Thus, each sub-scale score ranges from 0 (not at all, worse outcome) to 4 (very much, better outcome) with a minimum total score of 0 (worst quality of life) to a maximum of 16 (good quality of life).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.94","spread":"0.83"},{"groupId":"OG001","value":"2.11","spread":"0.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.18","spread":"0.93"},{"groupId":"OG001","value":"2.34","spread":"0.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.02","spread":"0.82"},{"groupId":"OG001","value":"3.30","spread":"0.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.03","spread":"0.90"},{"groupId":"OG001","value":"2.88","spread":"0.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.55","spread":"0.90"},{"groupId":"OG001","value":"2.93","spread":"0.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.88","spread":"0.77"},{"groupId":"OG001","value":"2.42","spread":"0.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.81","spread":"0.92"},{"groupId":"OG001","value":"1.75","spread":"0.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.88","spread":"0.86"},{"groupId":"OG001","value":"1.88","spread":"0.78"}]}]}]},{"type":"PRIMARY","title":"Pain-related Distress","description":"Patients in each arm will each have 9 measures: daily scores averaged over 1 week with baseline to week 8. Pain-related distress scale is from 0 (no pain) to 10 (worst pain).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.32","spread":"2.50"},{"groupId":"OG001","value":"4.87","spread":"2.64"}]}]}]},{"type":"PRIMARY","title":"Pain Duration","description":"Pain duration in hours 0 to 24","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.40","spread":"6.06"},{"groupId":"OG001","value":"11.31","spread":"7.78"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":42},"commonTop":["fatigue","drowsiness, somnolence","nausea","constipation","cough"]}}}